Elanco Animal Health Hits New 52-Week High of $22.25

Elanco Animal Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 22.25 on October 24, 2025. This achievement marks a notable increase from its 52-week low of USD 8.02, reflecting a robust performance over the past year.
In the last 12 months, Elanco has demonstrated a strong performance with a gain of 20.89%, outperforming the S&P 500, which recorded a 16.9% increase during the same period. The company's market capitalization stands at USD 9,464 million, classifying it as a small-cap entity within the Pharmaceuticals & Biotechnology industry.

Financial metrics indicate a price-to-earnings (P/E) ratio of 14.00, suggesting a competitive valuation relative to its earnings. Additionally, Elanco maintains a debt-to-equity ratio of 0.54, highlighting a manageable level of debt. The return on equity is reported at 7.26%, and the price-to-book ratio is 1.40, further illustrating the company's financial health. This recent price movement underscores Elanco's position in the market and its operational performance over the past year.